Issues with Effectiveness, Resistance and Ethics in Antimicrobial Clinical Trials How We Can Do Better Issues with Effectiveness, Resistance and Ethics.

Slides:



Advertisements
Similar presentations
Design of Clinical Trials for Treatment of Invasive Fungal Infections John H. Powers, MD FACP FIDSA Senior Medical Scientist SAIC in support of Collaborative.
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
24 April Elements of Research Ethics Review II Social Value Malik Fernando M.B.,Ch.B. (Bristol)
Substantiation of Health Claims in Advertising: Probiotics Richard L. Cleland Division of Advertising Practices Federal Trade Commission.
Clinical Trial Design in Acute Bacterial Sinusitis Considerations for Future Guidance Clinical Trial Design in Acute Bacterial Sinusitis Considerations.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
1 Issues in Selection of Deltas in Non-Inferiority Trials : Acute Bacterial Meningitis and Hospital- Acquired Pneumonia John H. Powers, M.D. Medical Officer.
Clinical Trials Importance in future therapies. What are the Requirements to Produce New Drugs? Drug must work significantly better than a control treatment.
Clinical Trials Medical Interventions
How does the process work? Submissions in 2007 (n=13,043) Perspectives.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Surrogate Endpoints in Infectious Diseases Trials: FDA Perspective Surrogate Endpoints in Infectious Diseases Trials: FDA Perspective John H. Powers, MD.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
1 Selection of  in Clinical Trials of Antimicrobial Therapy - Acute Exacerbation of Chronic Bronchitis Susan D. Thompson, M.D. February 19, 2002.
Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.
1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.
Clinical Trials Considerations in Primary Bacteremia due to Staphylococcus aureus Clinical Trials Considerations in Primary Bacteremia due to Staphylococcus.
1 Ethical issues in clinical trials Bernard Lo, M.D. February 10, 2010.
Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
1 Ethical issues in clinical trials Bernard Lo, M.D. February 7, 2008.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.
CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.
History of Pediatric Labeling
Measuring Effectiveness in Trials of Acute Bacterial Sinusitis Measuring Effectiveness in Trials of Acute Bacterial Sinusitis John H. Powers, MD Lead Medical.
Perspectives on Enhancing Consumer Outcomes with Topical Antifungals
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Committee Meeting December 14 & 15, Anti-Infective.
1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Medical Research and Clinical Trials Rels 300 / Nurs October 2015.
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
Anti-Infective Drugs Advisory Committee Meeting September 12, Factive® (gemifloxacin) Proposed for the treatment of Acute Bacterial Sinusitis Oscient.
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA.
Study Designs for Acute Otitis Media: What can each design tell us? C. George Rochester, Ph.D. Anti-Infective Advisory Committee Meeting, July 11, 2002.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
GCP (GOOD CLINICAL PRACTISE)
Patient Focused Drug Development An FDA Perspective
Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.
FDA’s IDE Decisions and Communications
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Clinical Trials Medical Interventions
Randomized Trials: A Brief Overview
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Critical Reading of Clinical Study Results
Clinical Trials.
Ethical Considerations for Pediatric Clinical Investigations
Research, Experimentation, & Clinical Trials
Regulatory Perspective of the Use of EHRs in RCTs
Pediatric Drug Development A Regulatory Perspective
Aparna Raychaudhuri, Ph. D
Presentation transcript:

Issues with Effectiveness, Resistance and Ethics in Antimicrobial Clinical Trials How We Can Do Better Issues with Effectiveness, Resistance and Ethics in Antimicrobial Clinical Trials How We Can Do Better John H. Powers, MD FACP FIDSA Former Lead Medical Officer for Antimicrobial Drug Development and Resistance Initiatives, FDA

2 Substantial Evidence of Effectiveness  FDA’s own regulations call for substantial evidence of effectiveness based on adequate and well-controlled trials  Substantial evidence not based on opinions of clinicians, use in clinical practice, or marketing success  Standards not meant to be applied prospectively only  “Totality of the evidence” has unclear meaning and is not the standard of substantial evidence

3  Noninferiority trials do not show that two drugs are “equivalent” or “as effective as” each other  Noninferiority trials designed to rule out how much less effective a new drug might be compared to an old drug  Need to first know whether the old drug is better than placebo and by how much  These principles outlined in FDA guidance that applies to all therapeutic areas since 2000 ICH E-10 guidance publication Resp Med 2002;96(11):

4 Not Just About the Margin  Enrolling patients who do not have the disease  Telithromycin vs cefuroxime axetil in ABS had 38.7% of total enrolled subjects in bacteriological per protocol analysis  Buchanan PP et al. Am J Rhinology 2003;17:  Applying margin from severe form of disease to less severe form of disease  Tunisian trial in intubated AECB patients does not apply to subjects enrolled in current NI trials  Nouira S et al. Lancet 2001;358:  Evaluating patients at time point beyond spontaneous resolution of disease  Acute otitis media resolves in 3-4 days without treatment but endpoint placed at day after initiation of therapy  Noninferiority trials limit ability to evaluate novel trial designs since they must keep constant the study design of the placebo controlled trials upon which they are based

5 Noninferiority Trials  Noninferiority trials are appropriate in serious and life- threatening diseases where benefit of antimicrobials on decreasing mortality is reliable, reproducible and large  Noninferiority trials do not provide evidence of effectiveness in self-resolving respiratory tract diseases  12 of 17 placebo controlled trials in ABS fail to show benefit of antimicrobials  9 of 14 placebo controlled trials in AECB fail to show benefit of antimicrobials  Published meta-analyses have methodological issues and are not appropriate basis for noninferiority trials  Do not evaluate all the available trials (Saint meta-analysis in AECB does not include 5 of 14 (36%) of PCTs)  Pool data across trials with very different designs  Evaluate subgroups of patients from placebo controlled trials

6

7

Ganaca et al n=50 Lindbaek et al n=127 Haye et al n=168 Hansen et al n=127 Wald et al n=93 Varonen et al n=146 van Buchem et al n=206 deSutter et al n=135 Axelsson et al n=142 Norrelund et al n=135 Kaiser et al n=265 a (77) b Bucher et al n=251 Garbutt et al n=161 Stalman et al n=186 Analysis of Efficacy in Placebo Controlled Trials in Acute Bacterial Sinusitis Kristo et al n=82 Lindbaek et al n=70 Merenstein et al n=135 a b Study 3011 Study 3005 Study 3002 cefuroxime d14 amox or amoxicillin-clav d14 azithromycin d8 pivampicillin d8 pencillin or lincomycin d10 amoxicillin d14 amox or doxy or penicillin d 14 amoxicillin or amox-clav d10 penicillin d7 azithromycin d14 amoxicillin or penicillin d10 amoxicillin d10 doxycycline d10 amoxicillin-clavulanate d14

Analysis of Placebo Controlled Trials in Acute Exacerbations of Chronic Bronchitis Elmes et al n=88 no significant difference in time to resolution of symptoms p = 0.20 oxytetracycline Fear et al n=62 no significant difference in time to resolution of symptoms p = 0.30 oxytetracycline d12 Elmes et al n= 56 no significant difference in investigator clinical assessment of matched pairs ampicillin d7 Petersen et al 1967 n=19 chloramphenicol d 10 Pines et al n=30 penicillin +streptomycin d14 Pines et al.1972 n=259 tetracycline or chloramphenicol d7 Nicotra et al n=40 no significant difference in mean change in Pa O2 between groups tetracycline d7 (first exacerbation only) Anthonisen et al. 1987a n = 116 (crossover) TMP-SMX or doxycycline d21 Manresa et al n=19 (not randomized) cefaclor d8 Berry et al 1960 n=53 oxytetracycline d14 Allegra et al 1991 n=335 amoxicillin-clavulanate d5 Jorgensen et al n=278 amoxicillin d8 Sachs et al n=71 amoxicillin or TMP-SMX d14 Nouira et al n=93 ofloxacin d30 Study 3003 Study 3007 Study 3013

10 Labeling  INDICATIONS AND USAGE SECTION “If there is a common belief that the drug may be effective for a certain use or if there is a common use of the drug for a condition, but the preponderance of evidence related to the use or condition shows that the drug is ineffective or that the therapeutic benefits of the product do not generally outweigh its risks, FDA may require that this section state that there is a lack of evidence that the drug is effective or safe for that use or condition.  21 CFR (c)(2)(ii)

11 Ethics  “Equipoise” is basic principle in clinical trials – patients should be enrolled in trials only if there is substantial uncertainty about which of the interventions would benefit the patients more  Declaration of Helsinki notes placebo controlled trials are ethical when:  Scientifically sound methodological issues to determine safety and efficacy of drug  Subjects not exposed to additional risks of serious harm  Patients in placebo groups may receive benefit of fewer drug related adverse events  Placebo controlled trials do not mean no treatment

12 Scientific Validity as Ethical Requirement  “It is well established that for research in human beings to be ethical it must be scientifically worthy…. An improperly designed study involving human subjects – one that could not possibly yield scientific facts relevant to the question under study is by definition unethical. A worthless study cannot possibly benefit anyone, least of all the subject himself. Any risk to the patient, no matter how small, cannot be justified. A study cannot become ethical by trading some deficiency in scientific worth for a superfluity of some other element.” Friedman B. IRB 1987;9(6):7-10. FIRST DO NO HARM

13 JAMA 2001;285(9):1206-8

14

15 Time to Move On  Need to improve on clinical trial design:  Placebo controlled trials to answer important basic questions about drug effectiveness in self-resolving  Pharmacodynamic analyses to choose most appropriate dose  Ensuring subjects in clinical trial have disease under study  Standardized, more accurate, more frequent measures using validated Patient Reported Outcomes instruments  Time to response as primary endpoint

16 Time to Resolution and Sample Size Sample Size Estimation Median Time to Resolution for Active agent Median Time to Resolution for Placebo

17 19 approvals for acute otitis media 20 approvals for acute bacterial sinusitis 29 approvals for acute exacerbations of chronic bronchitis (*5 withdrawn due to adverse effects) 68 NDA approvals